RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.

Zacks Investment Research • Oct 15, 2026

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

Agreement marks the Company's second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction Agreement marks the Company's second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction

GlobeNewsWire • Oct 14, 2026

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.

Zacks Investment Research • Oct 14, 2026

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.

Zacks Investment Research • Oct 8, 2026

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

Ultragenyx Pharmaceutical (NASDAQ:RARE) shares rose over 3.2% on Wednesday morning after the biopharmaceutical company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The voucher was awarded to Ultragenyx after the US Food and Drug Administration approved GENGLYCOS, also known as DTX401, for glycogen storage disease (GSD) type Ia.

Proactive Investors • Oct 7, 2026

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. Ultragenyx received the PRV upon U.S. Food and Drug Administration (FDA) approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, the first treatment designed to address the underlying cause of glycogen storage disease type Ia (GSDIa).

GlobeNewsWire • Oct 7, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

GlobeNewsWire • Oct 6, 2026

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.

Zacks Investment Research • Oct 5, 2026

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational gene therapy, rebisufligene etisparvovec, for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A.

GlobeNewsWire • Oct 2, 2026

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript

Seeking Alpha • Sep 18, 2026